Tradestie Institutional Equity Comparison Engine

MRNA vs REGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REGN Overall Edge

REGN Captures Institutional Edge (3โ€“1 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus REGN at 14.8x Forward P/E and 30.4% operating margin (+36.3% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner REGN
MRNA 23.0x vs REGN 14.8x Fwd P/E
Growth & Margin Winner REGN
Op Margin -80.8% vs 30.4% ยท YoY +29.2% vs +36.3%
Momentum & Technical Winner MRNA
1Y +706.5% vs +31.0% ยท 52W Pos 67% vs 82%
Options & Structure Winner REGN
CONSOLIDATION (52nd %ile IV) vs CONSOLIDATION (6th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$920.69
-0.29% 1D
Market Cap $95.5B
1M Return +12.4%
1Y Return +31.01%
Forward P/E 14.8x
Unified AI Score
46.0 / 100 HOLD
Tech 29.0 Fund 49.0 Flow 69.0 Mom 56.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% REGN +31.01% Spread: +675.44 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRNA Revenue REGN Revenue MRNA Op. Margin REGN Op. Margin Margin Edge
FY2018 $140M $5.15B -306.0% 49.3% REGN
FY2019 $60M $6.56B -906.8% 33.7% REGN
FY2020 $800M $8.50B -95.0% 42.1% REGN
FY2021 $18.5B $16.1B 72.0% 55.7% MRNA
FY2022 $19.3B $12.2B 48.9% 38.9% MRNA
FY2023 $6.85B $13.1B -61.9% 30.9% REGN
FY2024 $3.24B $14.2B -121.9% 28.1% REGN
FY2025 $1.94B $14.3B -158.1% 24.9% REGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (0) vs REGN (10)
Institutional Metric MRNA REGN Criterion Row Winner
Market Capitalization Scale $80.7B $95.5B Larger Scale REGN
Trailing P/E Ratio Valuation 23.0x 20.4x Lower Multiple REGN
Forward P/E Ratio Valuation 23.0x 14.8x Lower Multiple REGN
Revenue Growth (YoY) Growth +29.2% +36.3% Higher Growth REGN
Operating Margin (TTM) Profitability -80.8% 30.4% Higher Margin REGN
Net Profit Margin Profitability -110.5% 28.5% Higher Margin REGN
Return on Equity (ROE) Capital Efficiency -34.5% 14.9% Higher ROE REGN
52-Week Range Position Momentum 67% ($22โ€“$281) 82% ($592โ€“$992) Stronger Trend REGN
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 0.30ฮฒ ยท 55% Vol Lower Realized Risk REGN
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 46.0 / 100 (HOLD) Higher Composite REGN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs REGN Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
REGN CONSOLIDATION
56d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live REGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor REGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.